Celyad Oncology S.A.
CYAD
Rank in Stocks
#29398
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Share Price
$0.16500743
Last synced: 2026-11-17
Market Cap
$7.39M
Change (1 day)
6.90%
Change (1 year)
-23.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Celyad Oncology S.A. (CYAD)
Category
Healthcare
EPS for Celyad Oncology S.A. (CYAD)
EPS as of June 2026 TTM: $0.09
According to Celyad Oncology S.A.'s latest financial reports, its current EPS (TTM) is $0.09. At the end of 2025 the company had an EPS of $0.02, an increase over its 2024 EPS of $-0.15.
EPS history for Celyad Oncology S.A. from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.09 | 357.50% |
| 2025 | $0.02 | -115.65% |
| 2024 | $-0.15 | -60.06% |
| 2023 | $-0.36 | -81.21% |
| 2022 | $-1.94 | 0.43% |
| 2021 | $-1.93 | 29.05% |
| 2020 | $-1.50 | -41.70% |
| 2019 | $-2.57 | -31.41% |
| 2018 | $-3.75 | -46.72% |
| 2017 | $-7.03 | 164.14% |
| 2016 | $-2.66 | -28.53% |
| 2015 | $-3.72 | 26.15% |
| 2014 | $-2.95 | -28.68% |
| 2013 | $-4.14 | 46.63% |
| 2012 | $-2.82 | 51.44% |
| 2011 | $-1.86 | 31.53% |
| 2010 | $-1.42 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 17,014.75% |
US
|
|
| $-7.08 | -7,837.70% |
US
|
|
| $-5.29 | -5,881.42% |
AU
|
|
| $21.56 | 23,462.84% |
NL
|
|
| $12.73 | 13,814.97% |
BE
|
Questions about Celyad Oncology S.A.'s earnings per share (EPS)
What is Celyad Oncology S.A.'s earnings per share (EPS)?
Celyad Oncology S.A.'s earnings per share (EPS) over the last twelve months is $0.09, as of Jun 2026.
What was Celyad Oncology S.A.'s earnings per share (EPS) in 2025?
In 2025, Celyad Oncology S.A.'s earnings per share (EPS) was $0.02, compared with $-0.15 in 2024.
How has Celyad Oncology S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Celyad Oncology S.A.'s earnings per share (EPS) was highest in 2025 ($0.02) and lowest in 2022 ($-1.94).
How does Celyad Oncology S.A.'s earnings per share (EPS) compare with similar companies?
Celyad Oncology S.A.'s earnings per share (EPS) ($0.09) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.